Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In...

Keywords

MedicinePioglitazoneMacrovascular diseaseInternal medicineMyocardial infarctionClinical endpointType 2 diabetesStroke (engine)PlaceboDiabetes mellitusRandomized controlled trialCardiologySurgeryEndocrinology

Affiliated Institutions

Related Publications

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein , Helen M. Colhoun , Gilles R. Dagenais +97 more

This multicentre, randomised, double-blind, placebo-controlled trial was done at 371 sites in 24 countries. Men and women aged at least 50 years with type 2 diabetes who had eit...

2019 The Lancet 2683 citations

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials

Christoph Stettler , Sabin Allemann , Peter Jüni +5 more

Uncertainty persists concerning the effect of improved long-term glycemic control on macrovascular disease in diabetes mellitus (DM). We performed a systematic review and meta-a...

2006 American Heart Journal 463 citations

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Philip Home , Stuart Pocock , Henning Beck‐Nielsen +6 more

2009 The Lancet 1385 citations

Age and gender bias in statin trials

Syamasis Bandyopadhyay

Cardiovascular disease is strongly age-related, and is the leading cause of death in older people. Several well-publicized trials have recently reported that statin drugs (HMG C...

2001 QJM 57 citations

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Peter Sever , Björn Dahlöf , Neil R Poulter +11 more

The lowering of cholesterol concentrations in individuals at high risk of cardiovascular disease improves outcome. No study, however, has assessed benefits of cholesterol loweri...

2003 The Lancet 3773 citations

Publication Info

Year: 2005
Type: article
Volume: 366
Issue: 9493
Pages: 1279-1289
Citations: 4090
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

4090

OpenAlex

Cite This

APA Style

                            
                                
                                    John Dormandy, 
                                
                                    B Charbonnel, 
                                
                                    D.J.A. Eckland
                                
                                et al.
                            
                            (2005). 
                            Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. 
                            The Lancet
                            , 366
                            (9493)
                            , 1279-1289.
                            https://doi.org/10.1016/s0140-6736(05)67528-9
                        

Identifiers

DOI: 10.1016/s0140-6736(05)67528-9